LPL may represent a new therapeutic target for treating glucose metabolism disorders, including type 2 diabetes mellitus and hepatic steatosis, such as non-alcoholic fatty liver disease. This evidence concerns the gene LPL and metabolic dysfunction-associated steatotic liver disease.